[1] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[2] |
CHEN Junyao, ZHANG Wentao, LIU Qiao, NIE Jianyun.
Clinical dilemma and systemic treatment strategy of triple-negative breast cancer in the elderly
[J]. China Oncology, 2023, 33(5): 506-516.
|
[3] |
SHAO Zhibo, YANG Benlong, WU Jiong.
Progress of important clinical trials of breast cancer in China in 2022
[J]. China Oncology, 2023, 33(2): 103-109.
|
[4] |
XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin.
New research advances and future prospect in precision treatment of triple-negative breast cancer
[J]. China Oncology, 2022, 32(8): 669-679.
|
[5] |
ZHOU Changshuai, YANG Yuechao, CUI Huanhuan, CHEN Lei, CHEN Xin, HAO Bin, TONG Tong, CAO Yiqun.
Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients
[J]. China Oncology, 2022, 32(4): 357-362.
|
[6] |
WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying .
Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration
[J]. China Oncology, 2021, 31(9): 775-782.
|
[7] |
HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang .
Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer
[J]. China Oncology, 2021, 31(3): 221-226.
|
[8] |
JIANG Mengyi , LU Yanqiao , WANG Hongxia .
Research progress and clinical significance of breast cancer heterogeneity
[J]. China Oncology, 2020, 30(5): 394-400.
|
[9] |
SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng .
Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer
[J]. China Oncology, 2020, 30(3): 186-191.
|
[10] |
LIU Yongzhi, ZHAO Yonghua, JIANG Hai, BAO Liping, WU Wei, SUN Qiang, JIANG Huichuan, JIA Zhaobo, HAO Shichao.
Clinicopathological characteristics and survival analysis of patients with mucinous breast carcinoma based on SEER database
[J]. China Oncology, 2019, 29(12): 955-960.
|
[11] |
CAO Xiaoshan, CONG Binbin.
The progress of treatment for triple-negative breast cancer in the era of precision medicine
[J]. China Oncology, 2019, 29(12): 971-976.
|
[12] |
ZHENG Xiaying, CHEN Junxia.
Expression of circRNA hsa_circ_0005320 in triple-negative breast cancer and its effect on cell proliferation
[J]. China Oncology, 2019, 29(11): 845-854.
|
[13] |
ZHU Xiuzhi, CHEN Li, JI Lei, GAO Yu, WANG Zhonghua.
Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors
[J]. China Oncology, 2019, 29(11): 899-905.
|
[14] |
LI Jiawei, SHI Zhaoting, HOU Yingmin, et al.
Clinicopathological and immunohistochemical basis for sonographic characteristics of triple-negative invasive breast cancer
[J]. China Oncology, 2019, 29(1): 37-44.
|
[15] |
YANG Rui, CHEN Junxia.
Effects of circular RNA hsa_circ_0058514 on the development and progression of triple-negative breast cancer
[J]. China Oncology, 2019, 29(1): 9-18.
|